Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Accumulated Expenses (2016 - 2026)

Catalyst Pharmaceuticals filings provide 17 years of Accumulated Expenses readings, the most recent being $125.2 million for Q1 2026.

  • On a quarterly basis, Accumulated Expenses rose 29369.88% to $125.2 million in Q1 2026 year-over-year; TTM through Mar 2026 was $125.2 million, a 29369.88% increase, with the full-year FY2025 number at $11.4 million, down 89.09% from a year prior.
  • Accumulated Expenses hit $125.2 million in Q1 2026 for Catalyst Pharmaceuticals, up from $11.4 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $125.2 million in Q1 2026 to a low of $425000.0 in Q1 2025.
  • Median Accumulated Expenses over the past 5 years was $48.1 million (2023), compared with a mean of $47.3 million.
  • Biggest five-year swings in Accumulated Expenses: tumbled 99.39% in 2025 and later soared 29369.88% in 2026.
  • Catalyst Pharmaceuticals' Accumulated Expenses stood at $53.6 million in 2022, then grew by 14.28% to $61.3 million in 2023, then surged by 69.88% to $104.1 million in 2024, then crashed by 89.09% to $11.4 million in 2025, then soared by 1002.72% to $125.2 million in 2026.
  • The last three reported values for Accumulated Expenses were $125.2 million (Q1 2026), $11.4 million (Q4 2025), and $119.6 million (Q3 2025) per Business Quant data.